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Introduction
Fetal atrial flutter (AF) is one of the most common fetal
tachyarrhythmias. The condition may be associated
with congestive heart failure, fetal hydrops, neurologic
morbidity, and intrauterine death. Transplacental
therapy with digoxin is the most common medical
treatment [1]. The efficacy of second-line drugs for
fetal AF reported in other studies has varied [1–3].
Sotalol is a `-blocking agent with additional class
III antiarrhythmic properties and has been reported
to have high rates of success in fetuses with AF [4,5].
Here, we present a case of fetal AF.
Case Report
A 30-year-old woman, gravida 1, para 0, without
antecedent obstetric or medical problems, came to our
hospital because of fetal tacchyarrhythmia noted at
25 weeks’ gestation. She had been prescribed 1 oral
digoxin 0.25 mg twice daily (bid) at another hospital.
Due to the side effects of digoxin (nausea, vomiting,
etc.) and persistent fetal tachyarrhythmia, she gave
up on the therapy and referred herself to our hospital
at 27 weeks’ gestation. Maternal thyroid function
and auto-immune disease surveys were within normal
limits. Fetal AF was diagnosed using M-mode echo-
cardiography and revealed atrial rates of approximately
480–520 beats per minute (bpm) and ventricular rates
of approximately 200–250 bpm with occasional satis-
factory atrioventricular block leading to ventricular rates
of 120 bpm (Figure 1). No structural anomalies were
noted on ultrasonography.
We started treatment with oral digoxin 0.25 mg
three times daily (tid) and kept within the recommended
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plasma digoxin therapeutic range. The fetal tachyar-
rhythmia persisted during 2 weeks of digoxin therapy.
We added sotalol 80 mg bid to the digoxin, as recom-
mended by a cardiologist. The fetal ventricular rates
gradually decreased when the sotalol dosage was
increased to 160 mg bid with digoxin at 0.75 mg/day.
After maintaining the dosage of the two drugs for
3 weeks, large variations in the fetal heart beat, from
220 to 100 bpm, were observed. During therapy, the
fetal heart beat decreased to a ventricular rate of ap-
proximately 80–160 bpm and the atrial rate to approxi-
mately 210 bpm (Figure 2). The dose was then tapered
according to the medical response. During the last 2
weeks of therapy, we only used 0.25 mg/day digoxin,
which kept the ventricular rhythm at approximately
100–160 bpm. No congestive heart failure in the fetus
was found during therapy, according to a series of echo-
cardiography films.
Labor was induced after the pregnancy had pro-
gressed to 37-4/7 weeks. A female baby weighing
3,000 g was born via vaginal delivery. After birth, a
complete electrocardiogram (ECG) showed AF with
occasional fibrillation (Figure 3). Echocardiography
revealed a small apical muscular ventricular septal
defect, a small patent ductus arteriosus, a moderate
degree of pulmonary artery hypertension, mild-to-
moderate tricuspid regurgitation, and arrhythmogenic
dilation of cardiomyopathy. Brain ultrasonography
showed no structural anomalies. Amiodarone 5–8 μg/
kg/min was used at first to control the tachyarrhythmia,
while heparin was used to prevent thrombus formation.
The ventricular rate had slowed but did not convert to
sinus rhythm. Cardioversion by direct current was
attempted but failed. Esmolol was ineffective. The
combination of digoxin, inderal, and amiodarone taken
orally controlled ventricular rates to approximately 60–
160 bpm and atrial rates to approximately 300 bpm;
oral aspirin was included to prevent thrombus formation.
The infant was taken home after the therapy was changed
to oral medication. Pediatricians recommended follow-
up of electrophysical studies for the infant. At 1 month,
the infant showed no neurologic sequelae.
Discussion
Fetal AF is defined as a rapid regular atrial rate of 300–
600 bpm with identical or slower ventricular heart rate.
The condition may be associated with congestive heart
failure, hydrops, neurologic morbidity, or intrauterine
death. Therefore, prenatal intervention is necessary.
The aim of intensive treatment is to convert to a sinus
rhythm with adequate ventricular rate, to prevent or
reverse congestive cardiac failure, and to avoid preterm
delivery.
Digoxin is one of the most commonly used drugs
to control fetal tachyarrhythmia. The dosage scheme
starts at 0.25 mg tid and increases to a maximum of
0.5 mg tid. The dose is adjusted to achieve a maternal
serum concentration in the therapeutic range of 0.8–
2.0 ng/mL. A retrospective study by Simpson and
Sharland included 127 fetuses with tachyarrythmias
[6], of which 105 had supraventricular tachycardia
(SVT) and 22 had AF. Fifty-two fetuses were hydropic
and 75 were non-hydropic. Digoxin monotherapy
converted most (62%) non-hydropic fetuses but
the response rate in hydropic fetuses was 20%. The
authors concluded that non-hydropic fetuses with
tachyarrhythmias have a good prognosis with trans-
placental treatment. In our patient, digoxin was used
initially at 0.25 mg tid, keeping the maternal serum
concentration within the therapeutic range. However,
the fetal tachyarrhythmia did not respond. In addition,
maternal side effects almost caused the patient to
discontinue therapy. Thus, we asked for another
medication to be used in the treatment.
Figure 1. Fetal atrial flutter before treatment, with atrial rates
of 500 bpm and ventricular rates of 231 bpm.
Figure 2. Fetal atrial flutter after sotalol/digoxin combined
treatment, with ventricular rates of about 67–150 bpm.
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Sotalol is a potent `-blocking agent with additional
class III antiarrhythmic properties and has mild or no
negative intropic effects. Class III agents prolong action
potential in the tissue, i.e. the QT interval. Sotalol is
contraindicated in patients with a baseline QT interval
greater than 450 msec, bronchial asthma or chronic
obstructive pulmonary disease, and creatinine clearance
of less than 40 mL/min. During sotalol treatment, QT
intervals need to be monitored by ECG, as do renal
function, and serum potassium and magnesium levels
[7,8]. Sotalol is eliminated through the kidneys so the
dose needs to be adjusted according to creatinine
clearance in patients with renal impairment. Sotalol can
transfer across the placenta rapidly and completely. The
initial suggested dosage scheme is 80 mg bid, after
which the dose is increased stepwise to a maximum of
160 mg tid [4]. Oudijk et al described fetal dysrhyth-
mia patients treated with sotalol [5]. Their retrospe-
ctive study included 10 fetuses with AF, 10 with SVT,
and one with ventricular tacycardia. Sotalol treatment
successfully established a sinus rhythm in eight fetuses
with AF and six fetuses with SVT. The mortality rate was
19%; three had SVT and one had AF. The authors con-
cluded that sotalol should be considered the drug of
choice to treat fetal AF due to the high success rate. In
our case, fetal AF had a poor response to digoxin treat-
ment and poor maternal tolerance (gastrointestinal dis-
comfort). Therefore, we added sotalol to the treatment.
We started the dose at 80 mg bid. The fetal ventricular
rhythm had improved by the time the dose reached 160
mg tid. We believe that sotalol is an effective treatment
for fetal AF and should be considered the best drug.
Lisowski et al conducted a similar study involving 44
fetuses with AF [9]. Among 20 hydropic fetuses, 10
received single-drug therapy (digoxin or sotalol), seven
received multi-drug therapy, and three received no
treatment. Of 24 non-hydropic fetuses, 13 received a
single drug (digoxin or sotalol), five received multiple
drugs (digoxin, procainamide, quinidine, flecainide,
propaphenone, sotalol), and six were delivered im-
mediately. The authors concluded that digoxin failed to
prevent recurrence at the time of delivery in 25% of
patients, whereas no recurrence of AF was reported with
sotalol, suggesting that the class III agent may be the
best future therapy.
Flecainide is a very effective drug in the treatment of
fetal SVT but concerns about possible pro-arrhythmic
effects have limited its use. Amiodarone has been
prescribed in preference to other drugs, but it is not
frequently used due to its poor tolerability. Verapamil
is contraindicated as it may increase mortality rates
[1].
In our case, although fetal sinus rhythm was not
reached after combined sotalol and digoxin treatment,
we delivered the infant at term, as suggested in the
study by Jaeggi et al [2]. They reported a retrospective
study of 49 fetuses with tachyarrhythmia, 15 of which
(30.6%) had AF. Eleven of these were treated with
maternal digoxin after which five converted to sinus
rhythm; four fetuses received no medication. Seven
neonates exhibited AF at birth but rhythm was controlled
within the first 2 days of life. The authors concluded that
most fetuses with therapy-resistant AF and the absence
of 1:1 atrioventricular conduction do not experience
Figure 3. Electrocardiogram of the neonate after birth prior to treatment shows atrial flutter with occasional atrial fibrillation.
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congestive heart failure, so do not need to be delivered
prematurely.
Several studies state that after delivery, fetal AF can
be controlled by medication or by direct current cardio-
version [2,3]. When sinus rhythm has been established,
recurrence of AF is rare. However, in our case, the neo-
nate had persistent AF even during postnatal treatment.
Despite no obvious anatomic deformities on
cardiography, atrial fibrillation was still noted. Therefore,
we concluded that the failure of intrauterine therapy
might be due to a combination of other tachyarrhythmia
patterns in the fetus.
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